Clinical Trials

  • REACT-AF: Evaluation of Blood-Thinning Medication in Patients with Atrial Fibrillation (AF)

    Principal Investigator:

    Angelo Bartolo Biviano, MD
    The purpose of this study is to assess whether it is safe and effective to stop oral anticoagulation medication (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF). Atrial fibrillation (AF) is the most common abnormal heart rhythm and is associated with an increased risk of stroke, heart failure, and death.

  • Real World Use Study of the Global Paradise System for People with High Blood Pressure

    Principal Investigator:

    Ajay J. Kirtane, MD
    We are doing this study to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This is an FDA approved device. Involvement in the study is expected to last approximately 60 months. Patients will be asked to collect blood pressure (BP) at home, to help us understand how ultrasound renal denervation impacts their blood pressure over time. Patients will receive home BP monitor device for the entire duration of the study and will be trained how to use it.

  • REBIRTH - Study of Bromocriptine in Women with Peripartum Cardiomyopathy (PPCM)

    Principal Investigator:

    Jennifer H Haythe, MD
    We are doing this study to test the use of a drug called bromocriptine for women with a condition called Peripartum cardiomyopathy (PPCM). The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill.

  • REBIRTH - Study of Bromocriptine in Women with Peripartum Cardiomyopathy (PPCM)

    Principal Investigator:

    Jennifer H Haythe, MD
    We are doing this study to test the use of a drug called bromocriptine for women with a condition called Peripartum cardiomyopathy (PPCM). The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill.

  • The BREAK II Study: Breaking up Prolonged Inactivity to Improve Cardiometabolic Health

    Principal Investigator:

    Keith Diaz, PhD
    U.S. Adults spend on average 11 to 12 hours a day sitting. Daily sedentary behavior is strongly associated with the risk of heart disease. The purpose of the BREAK II research study is to answer two questions: (1) How frequently should periods of prolonged sedentary time be interrupted? and (2) What is the appropriate duration or length of time of these breaks in sedentary time? If you are 18 years old or older and have no history of chronic diseases, and no physical disability preventing ability to walk and a non-smoker, you may be eligible for this study. Participants will receive up to $...

  • The CORCINCH-HF Study: Study of AccuCinch in Patients with Symptomatic Heart Failure with Reduced Ejection Frraction (HFrEF)

    Principal Investigator:

    Gabriel Tal Sayer, MD
    This is a prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Repair System in patients with heart failure and reduced ejection fraction (HFrEF).

  • The MAVERIC Trial

    Principal Investigator:

    Dor Lotan, MD
    The main purpose of the study is to evaluate if treatment with CardioRX will prevent pericarditis recurrences after the therapy with IL-1 blocker (medication to reduce inflammation) has been stopped. You are being asked to join the study because you have recurrent pericarditis. Pericarditis is inflammation of the percardium (double layer sac that surrounds the heart). The pericardium allows your heart to move freely with each heartbeat. Recurrent pericarditis is an episode of pericarditis that occurs after a symptom-free period of more than 4 weeks after the last episode. CardioRX is the...

  • The PROTECT IV Trial

    Principal Investigator:

    Michael B Collins, MD
    This is a Prospective, multicenter, randomized, parallel-controlled, open-label two-arm trial with an adaptive design that will randomize about 1252 subjects at approximately 120 US and international centers. The study is looking to see if a device called the Impella device will improve the way the heart works as well as if health is improved as compared to what is currently used for patients with reduced left-sided heart function. Participants will be assigned by the flip of a coin to receive the Impella device, or assigned to receive standard of care treatment. Participants will have a...

  • TTVR Early Feasibility Study in Patients with Symptomatic Severe Tricuspid Regurgitation - Medtronic

    Principal Investigator:

    Susheel Kumar Kodali, MD
    This is a research study for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the heart's tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart has to pump more blood with each beat to push the same amount of blood forward. The goal of this study is to gain early clinical insight into how the Intrepid transcatheter tricuspid valve replacement (TTVR) system device performs. There is a need for alternative and less invasive treatment options to treat this...

  • Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (HI-PEITHO)

    Principal Investigator:

    Sanjum Sethi, MD MPH
    The purpose of this study is to determine whether treatment with anticoagulation medications incombination with the EkoSonicTM Endovascular device with a dose of a clot-dissolving drug(thrombolytic) can reduce the risk of death and other serious problems when compared to anticoagulation medication alone. Other measurements will be taken to observe your overall health and quality of life for one year after treatment.

Pages